Quantcast

Shire plc: Results of the Annual General Meeting Held on April 28, 2009

April 28, 2009

DUBLIN, April 28 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP, NASDAQ:
SHPGY), the global specialty biopharmaceutical company, announces that at its
Annual General Meeting today, all resolutions contained in the notice of
meeting were duly passed and the results of the poll are as follows:

                                        For*      Against  Withheld**
    1.     To receive the
           Company's accounts
           together with the
           director's and
           auditor's reports    385,589,148    2,271,000     26,380
    2.     To approve the
           Remuneration Report  307,647,526   60,796,610 19,442,392
    3.     To elect Dr Barry
           Price as a Director
           of the Company       356,441,471   31,425,618     19,439
    4.     To re-appoint
           Deloitte LLP as
           Auditors of the
           Company              387,555,848      311,630     19,050
    5.     To authorize the
           Audit, Compliance
           and Risk Committee
           to determine the
           remuneration of the
           Auditors             387,180,598      671,746     34,184
    6.     To authorize the
           allotment of shares  332,997,412   54,868,377     20,739
    7.     To authorize the
           disapplication of
           pre-emption rights   387,558,665      297,124     30,739
    8.     To authorize market
           purchases            387,693,316      173,212     20,000

    * These figures include discretionary votes

** A vote “withheld” is not a vote in law and is not counted in the
calculation of the votes “for” or “against” a resolution.

Two copies of all resolutions passed, other than resolutions concerning
ordinary business, will shortly be submitted to the UK Listing Authority and
will be available for inspection at the UK Listing Authority’s Document
Viewing Facility, which is situated at the Financial Services Authority, 25
The North Colonnade, Canary Wharf, London E14 5HS.

Notes to Editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire’s in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website:
http://www.shire.com.

    For further information please contact:

    Shire plc:

    Tony Guthrie,
    Deputy Company Secretary,
    +44(0)1256-894746

    Investor Relations

    Clea Rosenfeld (Rest of the World)
    +44-1256-894-160

    Eric Rojas (North America)
    +1-617-551-9715

    Media

    Jessica Mann (Rest of the World)
    +44-1256-894-280

    Matthew Cabrey (North America)
    +1-484-595-8248

    Jessica Cotrone (North America)
    +1-617-613-4640

SOURCE Shire Plc


Source: newswire



comments powered by Disqus